Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan Olson

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
The Lancet. Neurology|February 17, 2016
Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trialJeffrey A Cohen, Douglas L Arnold, Giancarlo Comi, et al.
Lancet (London, England)|June 6, 2002
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialStephen B Hanauer, Brian G Feagan, Gary R Lichtenstein, et al.
Gastroenterology|February 6, 2004
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's diseasePaul Rutgeerts, Brian G Feagan, Gary R Lichtenstein, et al.
Gastrointestinal Endoscopy|February 28, 2006
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's diseasePaul Rutgeerts, Robert H Diamond, Mohan Bala, et al.
Journal of Pediatric Gastroenterology and Nutrition|June 30, 2009
Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACHWallace Crandall, Jeffrey Hyams, Subra Kugathasan, et al.
The New England Journal of Medicine|May 5, 2016
Ozanimod Induction and Maintenance Treatment for Ulcerative ColitisWilliam J Sandborn, Brian G Feagan, Douglas C Wolf, et al.
Gastroenterology|February 28, 2007
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in childrenJeffrey Hyams, Wallace Crandall, Subra Kugathasan, et al.
The American Journal of Gastroenterology|April 12, 2006
Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's diseaseGary R Lichtenstein, Allan Olson, Suzanne Travers, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 17, 2008
Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH studyMeena Thayu, Mary B Leonard, Jeffrey S Hyams, et al.
The New England Journal of Medicine|December 13, 2005
Infliximab for induction and maintenance therapy for ulcerative colitisPaul Rutgeerts, William J Sandborn, Brian G Feagan, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
The Lancet. Neurology|February 17, 2016
Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trialJeffrey A Cohen, Douglas L Arnold, Giancarlo Comi, et al.
Lancet (London, England)|June 6, 2002
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialStephen B Hanauer, Brian G Feagan, Gary R Lichtenstein, et al.
Gastroenterology|February 6, 2004
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's diseasePaul Rutgeerts, Brian G Feagan, Gary R Lichtenstein, et al.
Gastrointestinal Endoscopy|February 28, 2006
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's diseasePaul Rutgeerts, Robert H Diamond, Mohan Bala, et al.
Journal of Pediatric Gastroenterology and Nutrition|June 30, 2009
Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACHWallace Crandall, Jeffrey Hyams, Subra Kugathasan, et al.
The New England Journal of Medicine|May 5, 2016
Ozanimod Induction and Maintenance Treatment for Ulcerative ColitisWilliam J Sandborn, Brian G Feagan, Douglas C Wolf, et al.
Gastroenterology|February 28, 2007
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in childrenJeffrey Hyams, Wallace Crandall, Subra Kugathasan, et al.
The American Journal of Gastroenterology|April 12, 2006
Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's diseaseGary R Lichtenstein, Allan Olson, Suzanne Travers, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 17, 2008
Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH studyMeena Thayu, Mary B Leonard, Jeffrey S Hyams, et al.
The New England Journal of Medicine|December 13, 2005
Infliximab for induction and maintenance therapy for ulcerative colitisPaul Rutgeerts, William J Sandborn, Brian G Feagan, et al.
Pageof 3